File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Comparison of atorvastatin and simvastatin in the long-term treatment of hyperlipidemia after kidney transplantation
  • Basic View
  • Metadata View
  • XML View
TitleComparison of atorvastatin and simvastatin in the long-term treatment of hyperlipidemia after kidney transplantation
 
AuthorsTse, KC1
Yao, Q1
Yip, PS1
Lam, MF1
Li, FK1
Lai, KN1
Chan, TM1
 
KeywordsAtorvastatin
Hypercholesterolemia
Kidney transplantation
Simvastatin
 
Issue Date2006
 
PublisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
 
CitationHong Kong Journal Of Nephrology, 2006, v. 8 n. 1, p. 17-23 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S1561-5413(09)60225-8
 
AbstractBackground: Hyperlipidemia is a common complication after kidney transplantation. However, there is little long-term data on the efficacy and tolerability of statin therapy in kidney transplant recipients. Methods: We performed a prospective 3-year study to investigate the effects of atorvastatin treatment in 15 hypercholesterolemic stable renal allograft recipients on maintenance immunosuppression with corticosteroid and cyclosporine. Results were compared with data from 15 historical controls matched for baseline hyperlipidemia and renal allograft function who had been treated with simvastatin. Results: Patients in the two treatment groups showed similar baseline characteristics. The average dosages of atorvastatin and simvastatin were 9.25 ± 2.82 mg and 8.38 ± 1.86 mg, respectively. Atorvastatin treatment reduced total cholesterol (TC) by 31.1%, 27.7%, 25.9% and 28.9%, and low-density lipoprotein (LDL) by 43.4%, 37.4%, 36.8% and 41.6%, after 3, 12, 24 and 36 months of treatment, respectively. A significant reduction in triglycerides (TG) was noted after 3 and 9 months, but was not sustained. High-density lipoprotein levels were unaltered. Reductions in TC and LDL after simvastatin treatment appeared less pronounced, although the differences did not reach statistical significance. At last follow-up, 90.9% of atorvastatin-treated patients achieved target LDL of less than 3.4 mmol/L, compared with 78.6% of the simvastatin group. No patients developed adverse reactions including abnormalities in liver enzyme or creatine kinase levels. Acute rejection was not observed, although one patient on simvastatin developed chronic allograft nephropathy. Conclusion: Atorvastatin and simvastatin demonstrated sustained efficacy in reducing the levels of TC and LDL in stable renal allograft recipients. While atorvastatin may be more potent than simvastatin in the treatment of hypercholesterolemia, its TG-lowering effect was not sustained with long-term treatment. The difference in the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves.
 
ISSN1561-5413
2012 SCImago Journal Rankings: 0.162
 
DOIhttp://dx.doi.org/10.1016/S1561-5413(09)60225-8
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorTse, KC
 
dc.contributor.authorYao, Q
 
dc.contributor.authorYip, PS
 
dc.contributor.authorLam, MF
 
dc.contributor.authorLi, FK
 
dc.contributor.authorLai, KN
 
dc.contributor.authorChan, TM
 
dc.date.accessioned2012-09-05T05:26:03Z
 
dc.date.available2012-09-05T05:26:03Z
 
dc.date.issued2006
 
dc.description.abstractBackground: Hyperlipidemia is a common complication after kidney transplantation. However, there is little long-term data on the efficacy and tolerability of statin therapy in kidney transplant recipients. Methods: We performed a prospective 3-year study to investigate the effects of atorvastatin treatment in 15 hypercholesterolemic stable renal allograft recipients on maintenance immunosuppression with corticosteroid and cyclosporine. Results were compared with data from 15 historical controls matched for baseline hyperlipidemia and renal allograft function who had been treated with simvastatin. Results: Patients in the two treatment groups showed similar baseline characteristics. The average dosages of atorvastatin and simvastatin were 9.25 ± 2.82 mg and 8.38 ± 1.86 mg, respectively. Atorvastatin treatment reduced total cholesterol (TC) by 31.1%, 27.7%, 25.9% and 28.9%, and low-density lipoprotein (LDL) by 43.4%, 37.4%, 36.8% and 41.6%, after 3, 12, 24 and 36 months of treatment, respectively. A significant reduction in triglycerides (TG) was noted after 3 and 9 months, but was not sustained. High-density lipoprotein levels were unaltered. Reductions in TC and LDL after simvastatin treatment appeared less pronounced, although the differences did not reach statistical significance. At last follow-up, 90.9% of atorvastatin-treated patients achieved target LDL of less than 3.4 mmol/L, compared with 78.6% of the simvastatin group. No patients developed adverse reactions including abnormalities in liver enzyme or creatine kinase levels. Acute rejection was not observed, although one patient on simvastatin developed chronic allograft nephropathy. Conclusion: Atorvastatin and simvastatin demonstrated sustained efficacy in reducing the levels of TC and LDL in stable renal allograft recipients. While atorvastatin may be more potent than simvastatin in the treatment of hypercholesterolemia, its TG-lowering effect was not sustained with long-term treatment. The difference in the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationHong Kong Journal Of Nephrology, 2006, v. 8 n. 1, p. 17-23 [How to Cite?]
DOI: http://dx.doi.org/10.1016/S1561-5413(09)60225-8
 
dc.identifier.doihttp://dx.doi.org/10.1016/S1561-5413(09)60225-8
 
dc.identifier.epage23
 
dc.identifier.hkuros132004
 
dc.identifier.issn1561-5413
2012 SCImago Journal Rankings: 0.162
 
dc.identifier.issue1
 
dc.identifier.scopuseid_2-s2.0-33646239177
 
dc.identifier.spage17
 
dc.identifier.urihttp://hdl.handle.net/10722/162971
 
dc.identifier.volume8
 
dc.languageeng
 
dc.publisherLippincott Williams & Wilkins Asia. The Journal's web site is located at http://www.hkjn.org/
 
dc.publisher.placeHong Kong
 
dc.relation.ispartofHong Kong Journal of Nephrology
 
dc.relation.referencesReferences in Scopus
 
dc.subjectAtorvastatin
 
dc.subjectHypercholesterolemia
 
dc.subjectKidney transplantation
 
dc.subjectSimvastatin
 
dc.titleComparison of atorvastatin and simvastatin in the long-term treatment of hyperlipidemia after kidney transplantation
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Tse, KC</contributor.author>
<contributor.author>Yao, Q</contributor.author>
<contributor.author>Yip, PS</contributor.author>
<contributor.author>Lam, MF</contributor.author>
<contributor.author>Li, FK</contributor.author>
<contributor.author>Lai, KN</contributor.author>
<contributor.author>Chan, TM</contributor.author>
<date.accessioned>2012-09-05T05:26:03Z</date.accessioned>
<date.available>2012-09-05T05:26:03Z</date.available>
<date.issued>2006</date.issued>
<identifier.citation>Hong Kong Journal Of Nephrology, 2006, v. 8 n. 1, p. 17-23</identifier.citation>
<identifier.issn>1561-5413</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/162971</identifier.uri>
<description.abstract>Background: Hyperlipidemia is a common complication after kidney transplantation. However, there is little long-term data on the efficacy and tolerability of statin therapy in kidney transplant recipients. Methods: We performed a prospective 3-year study to investigate the effects of atorvastatin treatment in 15 hypercholesterolemic stable renal allograft recipients on maintenance immunosuppression with corticosteroid and cyclosporine. Results were compared with data from 15 historical controls matched for baseline hyperlipidemia and renal allograft function who had been treated with simvastatin. Results: Patients in the two treatment groups showed similar baseline characteristics. The average dosages of atorvastatin and simvastatin were 9.25 &#177; 2.82 mg and 8.38 &#177; 1.86 mg, respectively. Atorvastatin treatment reduced total cholesterol (TC) by 31.1%, 27.7%, 25.9% and 28.9%, and low-density lipoprotein (LDL) by 43.4%, 37.4%, 36.8% and 41.6%, after 3, 12, 24 and 36 months of treatment, respectively. A significant reduction in triglycerides (TG) was noted after 3 and 9 months, but was not sustained. High-density lipoprotein levels were unaltered. Reductions in TC and LDL after simvastatin treatment appeared less pronounced, although the differences did not reach statistical significance. At last follow-up, 90.9% of atorvastatin-treated patients achieved target LDL of less than 3.4 mmol/L, compared with 78.6% of the simvastatin group. No patients developed adverse reactions including abnormalities in liver enzyme or creatine kinase levels. Acute rejection was not observed, although one patient on simvastatin developed chronic allograft nephropathy. Conclusion: Atorvastatin and simvastatin demonstrated sustained efficacy in reducing the levels of TC and LDL in stable renal allograft recipients. While atorvastatin may be more potent than simvastatin in the treatment of hypercholesterolemia, its TG-lowering effect was not sustained with long-term treatment. The difference in the therapeutic efficacy between the two drugs might have been due to dose rather than to the drugs themselves.</description.abstract>
<language>eng</language>
<publisher>Lippincott Williams &amp; Wilkins Asia. The Journal&apos;s web site is located at http://www.hkjn.org/</publisher>
<relation.ispartof>Hong Kong Journal of Nephrology</relation.ispartof>
<subject>Atorvastatin</subject>
<subject>Hypercholesterolemia</subject>
<subject>Kidney transplantation</subject>
<subject>Simvastatin</subject>
<title>Comparison of atorvastatin and simvastatin in the long-term treatment of hyperlipidemia after kidney transplantation</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1016/S1561-5413(09)60225-8</identifier.doi>
<identifier.scopus>eid_2-s2.0-33646239177</identifier.scopus>
<identifier.hkuros>132004</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-33646239177&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>8</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>17</identifier.spage>
<identifier.epage>23</identifier.epage>
<publisher.place>Hong Kong</publisher.place>
</item>
Author Affiliations
  1. The University of Hong Kong